Zylox-Tonbridge (ZYLOXTB) Targets 10% Economic Interest in LifeTech Through HK$1.48 Billion Deal and Launches HK$875.60 Million Premium Share Placement

Bulletin Express11-06

Hong Kong – 6 November 2026 – Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) has signed definitive agreements to acquire an indirect stake in LifeTech Scientific Corporation and to raise new capital via a premium H-share placement.

Key Transaction Terms 1. LifeTech Subscription • Lighthouse SPV, currently wholly owned by GL Lighthouse One, will subscribe for 926.34 million new LifeTech shares at HK$1.60 per share, totalling HK$1.48 billion. • The new shares represent 16.7 % of LifeTech’s enlarged share capital. • Zylox-Tonbridge will simultaneously acquire 60 % of Lighthouse SPV for HK$889.30 million, giving it 60 % of Lighthouse SPV’s 16.7 % voting rights in LifeTech—an effective 10 % economic interest. • Funding: Lighthouse SPV will use internal resources plus external debt; Zylox-Tonbridge will deploy internal funds.

2. H-Share Placement • Zylox-Tonbridge will issue 39.80 million new H shares to GL Lighthouse Three at HK$22.00 per share, a 13.5 % premium to the 6 November closing price and a 15.4 % premium to the five-day average. • Gross proceeds are estimated at HK$875.60 million; net proceeds after expenses are expected to be HK$863.60 million. • The new shares equal 12.1 % of the current issued share base (excluding treasury shares) and 10.8 % post-issue. • Combined with an existing 22.50 million-share holding, GL Capital-related entities will control 62.30 million Zylox-Tonbridge H shares, or roughly 16.9 % of the enlarged share capital.

LifeTech Financial Snapshot • Revenue: RMB1.30 billion (2024), RMB1.37 billion (2025), RMB600.80 million (H1 2026). • Net profit/(loss): RMB168.50 million (2024), RMB112.40 million (2025), RMB-48.30 million (H1 2026). • As of 30 June 2026, total assets were RMB4.75 billion and net assets RMB3.27 billion.

Strategic Rationale The board expects the transaction set to: • Establish a multi-segment vascular intervention platform spanning neurovascular, peripheral, aortic and structural heart disease devices. • Leverage LifeTech’s 20-year operating base, domestic leadership and expanding international footprint. • Add proven R&D capabilities, including first-in-class products such as G-Branch and bioresorbable metal stents.

Regulatory & Completion Conditions • Both the LifeTech subscription and the H-share placement fall under “discloseable transaction” thresholds; no shareholder vote is required. • Closings are subject to customary conditions, including Stock Exchange listing approvals and PRC regulatory filings. • The LifeTech second-tranche issuance and Zylox-Tonbridge’s subscription for Lighthouse SPV shares are inter-conditional and are expected to complete concurrently.

Capital Use Net placement proceeds of HK$863.60 million will fund future investments or acquisitions, with full deployment targeted by end-2028.

Share Count Impact Issued shares (excluding treasury) will rise from 329.84 million to 369.64 million upon completion of the placement.

Cautionary Note The transactions are conditional and may not proceed if precedent conditions are not fulfilled.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment